Therapeutic compositions comprising extracts of propolis and uses thereof

A composition, a technology of a pharmaceutical composition, applied in the fields of anti-gastrointestinal cancer composition, composition for treatment and prevention of gastrointestinal cancer, capable of solving problems such as no symptoms, delay in diagnosis, etc.

Active Publication Date: 2015-12-16
MANUKA HEALTH NEW ZEALAND
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diagnosis is often delayed because symptoms may not appear early in the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic compositions comprising extracts of propolis and uses thereof
  • Therapeutic compositions comprising extracts of propolis and uses thereof
  • Therapeutic compositions comprising extracts of propolis and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0302] This example describes the evaluation of the anti-gastrointestinal cancer activity of propolis fractions produced by preparative chromatography. This study was performed in the colon cancer adenocarcinoma cell line DLD-1 using a proliferation assay.

[0303] Materials and methods

[0304] The test samples shown in Table 2 below were evaluated for their ability to modulate the viability and proliferation of human colorectal adenocarcinoma cells (DLD-1 ) as assessed by the MTT assay. A positive control, 5-fluorouracil (5-FU), was included in the study in addition to an unsupplemented cell control (negative control). Test samples were obtained by grading propolis tinctures.

[0305] Production of Propolis Tincture Fractions by Column Chromatography

[0306] Fractionation was performed using a glass column packed with a Merck Lichroprep CI8 reverse phase stationary phase (16 x 4 cm) that had been washed with methanol (MeOH, 200 mL) and equilibrated with 20% aqueous EtOH ...

Embodiment 2

[0357] This example describes the evaluation of the anti-gastrointestinal cancer activity of compositions of the invention compared to pure compound standards. This study was performed in the colon adenocarcinoma cell line DLD-1 using a proliferation assay as described in Example 1.

[0358] Preparative HPLC

[0359] The 20%, 30%, 60% and 90% EtOH aqueous elution fractions from Example 1 were further fractionated by preparative HPLC. The dried 20% and 30% EtOH fractions were dissolved in EtOH / H 2 O (1:1), while the 60% and 90% EtOH fractions were dissolved in pure EtOH. Each solution was chromatographically analyzed by preparative HPLC on a Phenomenex Synergi4|i,-RPMax80A250×30mmC-12 column using a Gilson321 preparative pump and an Agilent1100 series diode array detector. Injection volumes between 0.5 and 1.5 mL were used. A flow rate of 20 mL / min was used. For the 20%, 30% and 60% EtOH fractions, an initial solvent composition of 70% water (with 0.1% trifluoroacetic acid...

Embodiment 3

[0412] This example describes the evaluation of the anti-gastrointestinal cancer activity of the compound 5-phenylpenta-2,4-dienoic acid isolated from NZ-derived European-type propolis as fraction S#14 60% F7 (Table 6, Example 2). This study was performed using proliferation assays of the human colon adenocarcinoma cell line DLD-1, the human colon carcinoma cell line HCT-116, the human gastric carcinoma cell line NCI-N87, and the human esophageal squamous carcinoma cell line KYSE-30.

[0413] The general method used for Examples 3 to 13 is shown below.

[0414] Materials and methods for antiproliferative assays in gastrointestinal cancer

[0415] 5-Phenylpenta-2,4-dienoate was assessed to regulate human colorectal adenocarcinoma cell line (DLD-1), human colon cancer cell line (HCT-116), human gastric cancer cell line ( NCI-N87) and human esophageal squamous cell carcinoma cell line (KYSE-30) viability and proliferation ability. In addition to an unsupplemented cell control ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2, 4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided.

Description

technical field [0001] The present invention relates to compositions for the treatment and prevention of gastrointestinal cancer. In particular, the present invention relates to anti-gastrointestinal cancer compositions comprising compounds derived from propolis, including anti-gastrointestinal cancer compositions comprising one or more propolis extracts enriched with one or more of these compounds . The use of such compositions to treat or prevent colorectal, throat and stomach cancers is particularly contemplated. Background technique [0002] Colorectal cancer is reported to be the second and third most common cancer in women and men, respectively, from developed countries. Colorectal cancer is more prevalent in developed countries - the United States, Australia, Europe and New Zealand have the highest rates - and its incidence is up to 10 times higher than in developing countries. While surgery can be effective, early detection is critical for positive surgical outcom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/12A61K31/216A61K31/235A61K31/353A61P35/00
CPCA61K31/12A61K31/192A61K31/222A61K31/353A61P35/00
Inventor K·保罗O·卡奇普尔K·米切尔
Owner MANUKA HEALTH NEW ZEALAND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap